AustralieFrV1, Main, Exploration, bibRecord, 007C92

Small molecules and targeted therapies in distant metastatic disease

Identifieur interne : 007C92 ( Main/Exploration ); précédent : 007C91; suivant : 007C93

Small molecules and targeted therapies in distant metastatic disease

Auteurs : P. Hersey [Australie] ; L. Bastholt [Danemark] ; V. Chiarion-Sileni [Italie] ; G. Cinat [Argentine] ; R. Dummer [Suisse] ; A. M. M. Eggermont [Pays-Bas] ; E. Espinosa [Espagne] ; A. Hauschild [Allemagne] ; I. Quirt [Canada] ; C. Robert [France] ; D. Schadendorf [Allemagne]

Source :

Annals of Oncology [ 0923-7534 ] ; 2009.

RBID : ISTEX:41572D8E13034FCF553D695DE9E72AB3F65F6E20

Descripteurs français

Pascal (Inist)
- Gène BRAF, Gène kit, Gène onc cellulaire, Inhibiteur, Maladie, Molécule petite, Mélanome malin, Métastase, Protooncogène, Protéine mTOR, Stade avancé, Thérapeutique ciblée, Traitement.
Wicri :
- topic : Maladie.

English descriptors

KwdEn :
- Advanced stage, BRAF Gene, C-Onc gene, Disease, Inhibitor, Malignant melanoma, Mammalian target of rapamycin, Metastasis, Protooncogene, Small molecule, Targeted therapy, Treatment, kit Gene.

Abstract

Chemotherapy, biological agents or combinations of both have had little impact on survival of patients with metastatic melanoma. Advances in understanding the genetic changes associated with the development of melanoma resulted in availability of promising new agents that inhibit specific proteins up-regulated in signal cell pathways or inhibit anti-apoptotic proteins. Sorafenib, a multikinase inhibitor of the RAF/RAS/MEK pathway, elesclomol (STA-4783) and oblimersen (G3139), an antisense oligonucleotide targeting anti-apoptotic BCl-2, are in phase III clinical studies in combination with chemotherapy. Agents targeting mutant B-Raf (RAF265 and PLX4032), MEK (PD0325901, AZD6244), heat-shock protein 90 (tanespimycin), mTOR (everolimus, deforolimus, temsirolimus) and VEGFR (axitinib) showed some promise in earlier stages of clinical development. Receptor tyrosine-kinase inhibitors (imatinib, dasatinib, sunitinib) may have a role in treatment of patients with melanoma harbouring c-Kit mutations. Although often studied as single agents with disappointing results, new targeted drugs should be more thoroughly evaluated in combination therapies. The future of rational use of new targeted agents also depends on successful application of analytical techniques enabling molecular profiling of patients and leading to selection of likely therapy responders.

Url:

DOI: 10.1093/annonc/mdp254

Affiliations:

Allemagne, Argentine, Australie, Canada, Danemark, Espagne, France, Italie, Pays-Bas, Suisse
Communauté de Madrid, Hollande-Méridionale, Schleswig-Holstein
Kiel, Madrid, Rotterdam

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Small molecules and targeted therapies in distant metastatic disease</title>
<author><name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
</author>
<author><name sortKey="Bastholt, L" sort="Bastholt, L" uniqKey="Bastholt L" first="L." last="Bastholt">L. Bastholt</name>
</author>
<author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V." last="Chiarion-Sileni">V. Chiarion-Sileni</name>
</author>
<author><name sortKey="Cinat, G" sort="Cinat, G" uniqKey="Cinat G" first="G." last="Cinat">G. Cinat</name>
</author>
<author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R." last="Dummer">R. Dummer</name>
</author>
<author><name sortKey="Eggermont, A M M" sort="Eggermont, A M M" uniqKey="Eggermont A" first="A. M. M." last="Eggermont">A. M. M. Eggermont</name>
</author>
<author><name sortKey="Espinosa, E" sort="Espinosa, E" uniqKey="Espinosa E" first="E." last="Espinosa">E. Espinosa</name>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
</author>
<author><name sortKey="Quirt, I" sort="Quirt, I" uniqKey="Quirt I" first="I." last="Quirt">I. Quirt</name>
</author>
<author><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C." last="Robert">C. Robert</name>
</author>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:41572D8E13034FCF553D695DE9E72AB3F65F6E20</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1093/annonc/mdp254</idno>
<idno type="url">https://api.istex.fr/document/41572D8E13034FCF553D695DE9E72AB3F65F6E20/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000C16</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C16</idno>
<idno type="wicri:Area/Istex/Curation">000C16</idno>
<idno type="wicri:Area/Istex/Checkpoint">000D13</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000D13</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Hersey P:small:molecules:and</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712592</idno>
<idno type="RBID">PMC:2712592</idno>
<idno type="wicri:Area/Pmc/Corpus">002240</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002240</idno>
<idno type="wicri:Area/Pmc/Curation">002090</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002090</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002725</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002725</idno>
<idno type="wicri:Area/Ncbi/Merge">000615</idno>
<idno type="wicri:Area/Ncbi/Curation">000615</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000615</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Hersey P:small:molecules:and</idno>
<idno type="wicri:Area/Main/Merge">008385</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0427939</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B24</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003500</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002845</idno>
<idno type="wicri:doubleKey">0923-7534:2009:Hersey P:small:molecules:and</idno>
<idno type="wicri:Area/Main/Merge">008814</idno>
<idno type="wicri:Area/Main/Curation">007C92</idno>
<idno type="wicri:Area/Main/Exploration">007C92</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Small molecules and targeted therapies in distant metastatic disease</title>
<author><name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, New South Wales</wicri:regionArea>
<wicri:noRegion>New South Wales</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Australie</country>
</affiliation>
<affiliation><wicri:noCountry code="syntax">???</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Australie</country>
</affiliation>
</author>
<author><name sortKey="Bastholt, L" sort="Bastholt, L" uniqKey="Bastholt L" first="L." last="Bastholt">L. Bastholt</name>
<affiliation wicri:level="1"><country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Oncology, Odense University Hospital, Odense</wicri:regionArea>
<wicri:noRegion>Odense</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V." last="Chiarion-Sileni">V. Chiarion-Sileni</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Oncology, Istituto Oncologico Veneto, Padova</wicri:regionArea>
<wicri:noRegion>Padova</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cinat, G" sort="Cinat, G" uniqKey="Cinat G" first="G." last="Cinat">G. Cinat</name>
<affiliation wicri:level="1"><country xml:lang="fr">Argentine</country>
<wicri:regionArea>Department of Oncology, Instituto de Oncologia Angel Roffo, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R." last="Dummer">R. Dummer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>Department of Dermatology, University of Zurich Hospital, Zurich</wicri:regionArea>
<wicri:noRegion>Zurich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Eggermont, A M M" sort="Eggermont, A M M" uniqKey="Eggermont A" first="A. M. M." last="Eggermont">A. M. M. Eggermont</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Surgical Oncology, Erasmus University Medical Center–Daniel den Hoed Cancer Center, Rotterdam</wicri:regionArea>
<placeName><settlement type="city">Rotterdam</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Espinosa, E" sort="Espinosa, E" uniqKey="Espinosa E" first="E." last="Espinosa">E. Espinosa</name>
<affiliation wicri:level="3"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Oncology, Hospital La Paz, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University of Kiel, Kiel</wicri:regionArea>
<placeName><region type="land" nuts="2">Schleswig-Holstein</region>
<settlement type="city">Kiel</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Quirt, I" sort="Quirt, I" uniqKey="Quirt I" first="I." last="Quirt">I. Quirt</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Princess Margaret Hospital, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C." last="Robert">C. Robert</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Dermatology, Institut Gustave Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Dermatology, University Hospital Essen, Essen</wicri:regionArea>
<wicri:noRegion>Essen</wicri:noRegion>
<wicri:noRegion>Essen</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="2009">2009</date>
<biblScope unit="volume">20</biblScope>
<biblScope unit="supplement">suppl_6</biblScope>
<biblScope unit="page" from="35">vi35</biblScope>
<biblScope unit="page" to="40">vi40</biblScope>
</imprint>
<idno type="ISSN">0923-7534</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>BRAF Gene</term>
<term>C-Onc gene</term>
<term>Disease</term>
<term>Inhibitor</term>
<term>Malignant melanoma</term>
<term>Mammalian target of rapamycin</term>
<term>Metastasis</term>
<term>Protooncogene</term>
<term>Small molecule</term>
<term>Targeted therapy</term>
<term>Treatment</term>
<term>kit Gene</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Gène BRAF</term>
<term>Gène kit</term>
<term>Gène onc cellulaire</term>
<term>Inhibiteur</term>
<term>Maladie</term>
<term>Molécule petite</term>
<term>Mélanome malin</term>
<term>Métastase</term>
<term>Protooncogène</term>
<term>Protéine mTOR</term>
<term>Stade avancé</term>
<term>Thérapeutique ciblée</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Chemotherapy, biological agents or combinations of both have had little impact on survival of patients with metastatic melanoma. Advances in understanding the genetic changes associated with the development of melanoma resulted in availability of promising new agents that inhibit specific proteins up-regulated in signal cell pathways or inhibit anti-apoptotic proteins. Sorafenib, a multikinase inhibitor of the RAF/RAS/MEK pathway, elesclomol (STA-4783) and oblimersen (G3139), an antisense oligonucleotide targeting anti-apoptotic BCl-2, are in phase III clinical studies in combination with chemotherapy. Agents targeting mutant B-Raf (RAF265 and PLX4032), MEK (PD0325901, AZD6244), heat-shock protein 90 (tanespimycin), mTOR (everolimus, deforolimus, temsirolimus) and VEGFR (axitinib) showed some promise in earlier stages of clinical development. Receptor tyrosine-kinase inhibitors (imatinib, dasatinib, sunitinib) may have a role in treatment of patients with melanoma harbouring c-Kit mutations. Although often studied as single agents with disappointing results, new targeted drugs should be more thoroughly evaluated in combination therapies. The future of rational use of new targeted agents also depends on successful application of analytical techniques enabling molecular profiling of patients and leading to selection of likely therapy responders.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Argentine</li>
<li>Australie</li>
<li>Canada</li>
<li>Danemark</li>
<li>Espagne</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Suisse</li>
</country>
<region><li>Communauté de Madrid</li>
<li>Hollande-Méridionale</li>
<li>Schleswig-Holstein</li>
</region>
<settlement><li>Kiel</li>
<li>Madrid</li>
<li>Rotterdam</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
</noRegion>
<name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
<name sortKey="Hersey, P" sort="Hersey, P" uniqKey="Hersey P" first="P." last="Hersey">P. Hersey</name>
</country>
<country name="Danemark"><noRegion><name sortKey="Bastholt, L" sort="Bastholt, L" uniqKey="Bastholt L" first="L." last="Bastholt">L. Bastholt</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Chiarion Sileni, V" sort="Chiarion Sileni, V" uniqKey="Chiarion Sileni V" first="V." last="Chiarion-Sileni">V. Chiarion-Sileni</name>
</noRegion>
</country>
<country name="Argentine"><noRegion><name sortKey="Cinat, G" sort="Cinat, G" uniqKey="Cinat G" first="G." last="Cinat">G. Cinat</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R." last="Dummer">R. Dummer</name>
</noRegion>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Eggermont, A M M" sort="Eggermont, A M M" uniqKey="Eggermont A" first="A. M. M." last="Eggermont">A. M. M. Eggermont</name>
</region>
</country>
<country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Espinosa, E" sort="Espinosa, E" uniqKey="Espinosa E" first="E." last="Espinosa">E. Espinosa</name>
</region>
</country>
<country name="Allemagne"><region name="Schleswig-Holstein"><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A." last="Hauschild">A. Hauschild</name>
</region>
<name sortKey="Schadendorf, D" sort="Schadendorf, D" uniqKey="Schadendorf D" first="D." last="Schadendorf">D. Schadendorf</name>
</country>
<country name="Canada"><noRegion><name sortKey="Quirt, I" sort="Quirt, I" uniqKey="Quirt I" first="I." last="Quirt">I. Quirt</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C." last="Robert">C. Robert</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007C92 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007C92 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:41572D8E13034FCF553D695DE9E72AB3F65F6E20
   |texte=   Small molecules and targeted therapies in distant metastatic disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Small molecules and targeted therapies in distant metastatic disease

Small molecules and targeted therapies in distant metastatic disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.